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Abstract
Airway pressure release ventilation (APRV) was first described in 1987 and defined as
continuous positive airway pressure (CPAP) with a brief release while allowing the
patient to spontaneously breathe throughout the respiratory cycle. The current
understanding of the optimal strategy to minimize ventilator-induced lung injury is
to “open the lung and keep it open”. APRV should be ideal for this strategy with the
prolonged CPAP duration recruiting the lung and the minimal release duration
preventing lung collapse. However, APRV is inconsistently defined with significant
variation in the settings used in experimental studies and in clinical practice. The
goal of this review was to analyze the published literature and determine APRV
efficacy as a lung-protective strategy. We reviewed all original articles in which the
authors stated that APRV was used. The primary analysis was to correlate APRV
settings with physiologic and clinical outcomes. Results showed that there was
tremendous variation in settings that were all defined as APRV, particularly CPAP and
release phase duration and the parameters used to guide these settings. Thus, it was
impossible to assess efficacy of a single strategy since almost none of the APRV
settings were identical. Therefore, we divided all APRV studies divided into two basic
categories: (1) fixed-setting APRV (F-APRV) in which the release phase is set and left
constant; and (2) personalized-APRV (P-APRV) in which the release phase is set based
on changes in lung mechanics using the slope of the expiratory flow curve. Results
showed that in no study was there a statistically significant worse outcome with
APRV, regardless of the settings (F-ARPV or P-APRV). Multiple studies demonstrated
that P-APRV stabilizes alveoli and reduces the incidence of acute respiratory distress
syndrome (ARDS) in clinically relevant animal models and in trauma patients. In
conclusion, over the 30 years since the mode’s inception there have been no strict
criteria in defining a mechanical breath as being APRV. P-APRV has shown great
promise as a highly lung-protective ventilation strategy.
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Review
Introduction
Stock and Downs first defined airway pressure release ventilation (APRV) as mainten-
ance of a continuous positive airway pressure (CPAP) that allows for spontaneous
breaths without significant airway pressure fluctuation and a brief cyclic release phase
for efficient ventilation (i.e., CPAP with release) [1]. However, the flexibility of this
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definition has become an Achilles heel of sorts since a wide variety of APRV settings
have all been used in the literature making comparison between studies impossible.
Therefore, the current acronym “APRV” is a nebulous term identifying a ventilator
mode without a precisely defined mechanical breath structure or ventilator settings.
Variability in settings, and thus mechanical breath structure, significantly changes how
the lung “sees” the breath being delivered. The first description of APRV published by
Stock et al. in 1987 was, “APRV is a new way to administer simultaneously a supportive
level of CPAP and assist CO2 elimination” [2]. Thus, the original definition of APRV
was simply CPAP with a release to eliminate CO2. CPAP with a release is a very general
description of a mechanical breath and can define all of the mechanical breaths seen in
Fig. 1. Indeed, all of these mechanical breaths were defined as APRV [2–5]. As can be
readily seen, the biggest difference between these APRV breaths is the duration at inspir-
ation and expiration. Since the original definition of APRV was CPAP with a release,
which did not specify the duration of the CPAP or release time, all of these breaths fit the
original definition. Over the 30 years since APRV was originally described, many combi-
nations of CPAP and release times have been used and all defined as APRV.
In this review, we examine published original research in both animal and human tri-
als in which the authors stated they utilized APRV, or a comparable but differently
named ventilator mode. Our goals with this review were as follows: (1) to examine the
historical evolution of APRV methodology; (2) to evaluate the efficacy of the APRV
methodologies versus conventional positive pressure ventilation (CPPV); and (3) to de-
termine if there are optimal APRV settings for maximal lung protection.
The evolution of APRV mostly revolves around modifying the CPAP and release time
durations (time at expiration—TLow) (Tables 1, 2, 3, and 4, %CPAP and TLow). However,
the most significant evolution in APRV has been the development of the ability to
personalize the expiratory duration to precisely meet the needs of the patient’s chan-
ging lung physiology. The advantage of this method is that expiratory duration is set to
maintain and open and stable the lung, regardless the level of lung pathology. Since
there was no consistency in the CPAP and release time duration in the published litera-
ture, we chose to separate APRV strategies into two categories: fixed- (F-APRV) and
personalized (P-APRV) APRV. If the expiratory duration or release time was not ad-
justed by mechanical changes in the lung, regardless of duration of CPAP or release
time, it was categorized as F-APRV. If the APRV strategy sets expiratory duration by
changes in lung mechanics, using the slope of the expiratory flow curve, it was catego-
rized as P-APRV (Fig. 1).
Methodology
A PubMed search of the terms “Airway Pressure Release Ventilation”, “APRV”, “Bi-
Vent”, “APRV/Biphasic” and “Bi-Level” and “Mechanical Ventilation” OR “Ventilator”
was conducted alone or in combination. English language studies between the years
1987 and 2015 were included, and studies testing non-invasive ventilator strategies
alone, reviews, editorials, and case studies were excluded, yielding 52 articles. Of the 60
articles, 32 were animal studies and 28 human studies (Tables 1, 2, 3, and 4). APRV
methodologies were analyzed by examining the following settings: (1) pressure during
inspiration/CPAP phase (PHigh); (2) time during inspiration/CPAP phase (THigh); (3)
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pressure during expiration/release phase (PLow); (4) time during expiration/release
phase (TLow); and (5) percent CPAP (%CPAP) to reflect the time spent at PHigh relative
to the entire breath duration THighTHighþTLow  100
 
. In addition, we assessed the factors
used to titrate these settings including respiratory rate or partial pressure of carbon di-
oxide (PCO2) for THigh and TLow and oxygenation or plateau pressure for PHigh.
Reviewing the evolution of APRV from its inception in 1987, we noted a major para-
digm shift in the way APRV is set. Initially, the variations in settings were to the in-
spiratory and expiratory duration time that were fixed and not adjusted to changes in
lung mechanics (Fig. 1a–c). In 2005, Habashi published a paper with a novel method of
setting the expiratory duration based on changing lung mechanics identified by the
slope of the expiratory flow curve (Figs. 1d and 2) [6]. This novel method of setting ex-
piratory duration sets this personalized APRV (P-APRV) strategy (Figs. 1d and 2) apart
from all other fixed setting-APRV (F-APRV) strategies.
Thus, we chose to divide our review of APRV efficacy into these two basic categories.
The F-APRV breath with a relatively short inspiratory time (THigh) occupying <90 % of
total cycle time (Fig. 1a–c) of each breath with a fixed expiratory time (TLow) that is not
adjusted based on changing lung mechanics. The second category originally described by
Habashi [6] was a P-APRV breath with the following settings: (1) the inspiratory pressure
(PHigh) is set to the desired plateau pressure,; (2) the THigh is typically set to occupy 90 %
of the total cycle time of each breath (Fig. 2a); (3) the TLow set based on changes in lung
mechanics by analyzing the slope of the expiratory flow curve (Fig. 2b); and (4) the expira-
tory pressure (PLow) is set at 0 cmH2O to minimize resistance to convective expiratory gas
flow and maximize ventilation. The short duration at end expiration prevents the airway
pressure from reaching atmospheric pressure, thus maintaining a positive end-expiratory
pressure. Based on the above criteria, the studies reviewed were placed into either the F-
APRV (Tables 1 and 3) or P-APRV (Tables 2 and 4) category.
Results
Animal (Tables 1 and 2) and human (Tables 3 and 4) studies were examined for APRV
settings and efficacy. As described above, the APRV methodologies were subdivided
into two categories: F-APRV; (Tables 1 and 3) and P-APRV (Tables 2 and 4). The ma-
jority of the animal studies (69 % of total) [2, 4, 7–26] and human studies (82 % of
total) [3, 27–48] were in the F-APRV category.
How expiratory duration was personalized
The expiratory flow curve is analyzed, and the ratio of the end-expiratory flow (EEF) to
the peak expiratory flow (PEF) is set so that the EEF/PEF ratio is 75 % [5, 49–62]
(See figure on previous page.)
Fig. 1 Comparison of APRV pressure waveforms. Artistic depiction of airway pressure waveforms, all of
which were defined as APRV, illustrating the significant variability in what has been defined as an APRV
breath. Stock in 1987 used 60 % CPAP with TLow of 1.27 s and a respiratory rate (RR) of 20 [2]. Davis in 1993
used a similar %CPAP, but decreased the RR by prolonging THigh and TLow [3]. Gama de Abreau in 2010
simulated conventional ventilation with a prolonged TLow and short THigh [4]. Finally, Roy in 2013 used a
very brief adaptive TLow and large THigh with 90 % CPAP [5]. Of note, though the ventilator pressure is set at
zero, this does not reflect true pressure as the brief TLow prevents full deflation of the lung, and thus
prevents end-expiratory pressure from reaching zero. Figures a–c are examples of fixed-APRV (F-APRV) and
figure d of personalized APRV (P-APRV)
Jain et al. Intensive Care Medicine Experimental  (2016) 4:11 Page 4 of 18
Table 1 Summary of animal studies utilizing F-APRV
First author Year n Animal Study design % CPAP TLow Findings
Stock [2] 1987 10 Mongrel dog Crossover
CPPV vs. APRV
58 % 1.27 s APRV improved oxygenation with lower PIP and
without cardiopulmonary compromise
Rasanen [21] 1988 10 Mongrel dog Crossover
CPPV vs. CPAP vs. APRV
50 % 1.5 s CPPV impaired circulatory function and tissue
oxygen balance, APRV had higher systemic
vascular resistance and decreased pulmonary
vascular resistance
Martin [17] 1991 7 Neonatal sheep Crossover
Spont vs. CPAP vs.
CPPV vs. APRV
50 % 1 s APRV augmented alveolar ventilation vs. CPAP,
and had lower Paw than PPV without compromised
cardiovascular function
Smith [23] 1995 5 Swine Crossover
CPAP vs. APRV
80 % 1.1 s exp flow 0 APRV maintains oxygenation without
hemodynamic compromise
Neumann [19] 2001 9 Swine Crossover
CPAP vs. APRV +/− PEEP
67 % 1 s APRV decreased O2 compared with CPAP, No
difference with PEEP
Hering [13] 2003 12 Swine Crossover
APRV +/− SB
50 % N/A APRV + SB increased oxygenation and
cardiovascular function
Wrigge [24] 2003 24 Swine Randomized prospective
APRV +/− SB
50 % 1.5–2 s APRV + SB increased oxygenation and
cardiovascular function
Neumann [20] 2005 20 Swine Randomized prospective
APRV +/− SB
50 % 1.5 s APRV + B increased ventilation in dependent
lung and decreased shunt
Hering [14] 2005 12 Swine Crossover
APRV vs. SB
50 % ~1.7 s APRV + SB improved oxygenation after
lung injury
Wrigge [25] 2005 22 Swine Randomized Prospective
APRV +/− SB
50 % 1.5–2 s APRV + SB redistributes ventilation to dependent
lung regions and counters cyclic collapse
Hering [12] 2008 12 Swine Crossover
APRV +/− SB
50 % N/A APRV + SB improved oxygenation and splanchnic
blood flow
Gama de Abreu [9] 2008 12 Swine Crossover
BiPAP + SB, PSV +/− sighs,
“noisy” PSV
N/A exp flow 0 “Noisy” CPPV improved oxygenation by
redistributing perfusion
Carvalho [7] 2009 5 Swine Crossover
PSV vs. BiPAP + SB













Table 1 Summary of animal studies utilizing F-APRV (Continued)
BiPAP + SB and pressure support had similar
oxygenation improvement and did not improve
aeration of dependent lung
Gama de Abreu [4] 2010 10 Swine Crossover
PSV vs. BiPAP + SB
25 % N/A BiPAP + SB had lower tidal volume with
comparable oxygenation and ventilation
distribution
Henzler [11] 2010 20 Swine Randomized prospective
APRV +/− SB
42 % ~1.2 s Elevated IAH impaired respiratory mechanics
regardless of SB
Kreyer [16] 2010 12 Swine Randomized Prospective
APRV +/− SB
50 % 1.5–2 s
exp flow 0
APRV + SB improved systemic blood flow and
cerebrospinal blood flow
Matsuzawa [18] 2010 21 Rabbit Randomized prospective
CPPV vs. LTV vs. APRV
95 % 0.15 s APRV reduced HMGB1 levels and lung water
Slim [22] 2011 7 Swine Case series
APRV
80 % N/A Increased Paw increased pulmonary capillary
wedge pressure and left atrial pressure, but these
may not correlate with end diastolic volume
Xia [26] 2011 24 Rabbit Randomized prospective
APRV +/− SB
50 % N/A APRV + SB improved oxygenation and
attenuated VILI
Carvalho [8] 2014 36 Swine Randomized prospective
APRV +/− SB
50 % N/A APRV + SB improved oxygenation and reduced
lung injury
Guldner [10] 2014 12 Swine Crossover
APRV +/− SB
50 % ~1 s Higher levels of SB reduce global lung stress and
strain with minimal changes in perfusion
Kill [15] 2014 24 Swine Randomized prospective
CPPV vs. Bilevel vs. Compression
synchronized ventilation
40 % 3.6 s CPPV and Bilevel usable during CPR, though
compression synchronized ventilation was best
Number of studies: 22
TLow time at low pressure, CPPV conventional positive pressure ventilation, LTV low tidal volume ventilation, CPAP continuous positive airway pressure, SB spontaneous breathing, PEEP positive end-expiratory pressure, PIP













Table 2 Summary of animal studies utilizing P-APRV
First author Year n Animal Study design %CPAP TLow Findings
Albert [49] 2011 22 Swine Randomized prospective, CPPV vs. LTV vs.
APRV vs. HFOV
90 % 50–75 % PEF APRV increased oxygenation and ventilation with reduced
cytokines compared to LTV
Roy [57] 2012 8 Swine Randomized prospective, CPPV vs. APRV 90 % 75 % PEF Early APRV prevented ARDS with improved oxygenation,
histopathology, and surfactant protein preservation
Emr [62] 2013 16 Rat Randomized prospective, spont vs. CPPV
vs. APRV
90 % 75 % PEF Early APRV prevented ARDS with improved oxygenation and
histopathology
Roy [5] 2013 12 Swine Randomized prospective, sham vs. LTV
vs. APRV
90 % 75 % PEF Early APRV prevented ARDS with improved oxygenation and
histopathology with reduced inflammatory markers
Roy [61] 2013 9 Rat Randomized prospective, CPPV vs. APRV 90 % 75 % PEF Early APRV prevented ARDS with improved oxygenation and
histopathology
Kollisch-Singule [55] 2014 8 Rat Randomized prospective, CPPV vs. APRV 90 % 10 or 75 % PEF APRV with low expiratory time reduced conducting airway
microstrain
Kollisch-Singule [54] 2014 6 Rat Randomized prospective, CPPV with PEEP
vs. APRV
90 % 10 or 75 % PEF APRV with low expiratory time reduced alveolar microstrain
Davies [52] 2015 22 Swine Randomized prospective, LTV vs. APRV 90 % 75 % PEF APRV increased oxygenation compared with LTV, APRV had a
“trend towards” increased cerebral ischemia.
Arrindell [51] 2015 19 Preterm swine Randomized prospective, CPPV vs. APRV N/A 75 % PEF APRV increased oxygenation without change in histopathology
or inflammatory markers
Kollisch-Singule [56] 2015 14 Rat Randomized prospective, uninjured vs. LTV
vs. APRV
90 % 75 % PEF APRV approximated control lungs best with increased
homogeneity compared to LTV. LTV with high PEEP
reduced heterogeneity.
Number of studies: 10
TLow time at low pressure, CPPV conventional positive pressure ventilation, LTV low tidal volume ventilation, CPAP continuous positive airway pressure, PEF peak expiratory flow, SB spontaneous breathing, PEEP positive













Table 3 Summary of human trials using F-APRV
First author Year n Study design %CPAP TLow Findings
Garner [31] 1988 14 Crossover
CPPV baseline with APRV
wean
N/A 1.5 s APRV maintained similar
oxygenation with >50 %
reduced PIP
Rasanen [40] 1991 50 Crossover
PEEP titrated CPPV
vs. APRV
50 % 1.5 s APRV maintained similar
oxygenation with >50 %
reduced PIP
Cane [28] 1991 18 Crossover
CPPV vs. APRV




Davis [3] 1993 15 Crossover
CPPV vs. APRV
32 % 2.6 ± 0.6 APRV maintained similar
oxygenation with >50 %
reduced PIP and reduced
PEEP
Chiang [29] 1994 18 Crossover
CPPV vs. APRV
66 % 1.5 s APRV maintained similar
oxygenation with >50 %
reduced PIP
Sydow [42] 1994 18 Crossover
CPPV vs. APRV
80 % 0.5–0.7 APRV maintained similar
oxygenation with decreased
A-a gradient after 8 h and
reduced PIP
Bratzke [27] 1998 20 Crossover
CPPV vs. APRV
88 % 1 APRV maintained similar
oxygenation with reduced PIP
Kaplan [36] 2001 12 Crossover
Inverse ratio PPV vs. APRV
85 % 0.8 APRV is safe, decreases PIP
and need for sedation/
paralytics/pressors, increases CI












Schultz [41] 2001 15 Crossover
CPPV vs. APRV
N/A N/A APRV maintained similar
oxygenation with >50 %
reduced PIP
Wrigge [45] 2001 14 Randomized prospective
APRV +/− automatic tube
compensation
N/A N/A APRV with tube compensation
increased end-expiratory lung
volume and minute ventilation
without affecting oxygenation
or cardiopulmonary status
Hering [34] 2002 12 Crossover
APRV +/− SB
N/A N/A APRV + SB had increased
renal blood flow and
glomerular filtration rate




APRV feasible in prone
positioning and increased
oxygenation at 24 h
Varpula [44] 2004 58 Randomized prospective
CPPV vs. APRV
80 % 1 APRV had similar mortality
and ventilator free days




APRV reduced PIP and
increased oxygenation
Liu [37] 2009 58 Retrospective case-control
CPPV vs. APRV
67 % ~1.5 APRV reduced pressor use/A-a
gradient and increased
oxygenation
Kamath [35] 2010 11 Retrospective cohort
CPPV vs. APRV
70 % 1.2 ± 0.9 APRV had no adverse effects
on blood pressure or urine
output
Gonzalez [32] 2010 468 Case matched
retrospective
CPPV vs. APRV
70 % N/A APRV maintained similar
oxygenation with reduced
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(Fig. 2b) based on the methodology described by Habashi [6] (Tables 2 and 4). The
TLow is thus personalized based on alterations in lung mechanics, identified by changes
in the slope of the expiratory flow curve (Fig. 2b). Using EEF/PEF ratio of 75 % results
in a brief TLow ranging from 0.3 to 0.6 s (Fig. 1d). However, recent animal experiments
have shown the optimal EEF/PEF ratio necessary to open and stabilize the lung is 75 %
[54–56].
F-APRV: inspiratory duration
There was considerable variability in the F-APRV settings (i.e., duration at inspir-
ation and expiration) in the papers reviewed, and in multiple papers, the settings
were not defined, and thus not included in this review. Swine, dogs, and rabbits
Table 3 Summary of human trials using F-APRV (Continued)
PIP and associated
increased tracheostomy rate




APRV had similar physiological
parameters despite increased
disease severity at baseline
Hanna [33] 2011 45 Retrospective case series
CPPV vs. APRV
N/A N/A APRV had increased P/F Ratio,
lung procurement rate with
similar graft survival rate
Maung [46] 2012 38 Retrospective case series
APRV




Maung [47] 2012 362 Retrospective case series
CPPV vs. APRV
N/A N/A APRV had increased ventilator
days.
Testerman [48] 2013 48 Case-matched
retrospective
APRV; obese vs. nonobese
N/A N/A APRV in morbidly obese similar
to nonobese, though morbidly
obese required extended care
after discharge more often
Number of studies: 23
TLow time at low pressure, CPPV conventional positive pressure ventilation, LTV low tidal volume ventilation, CPAP
continuous positive airway pressure, PEF peak expiratory flow, SB spontaneous breathing, PEEP positive end-expiratory
pressure, PIP peak inspiratory pressure
Table 4 Summary of human trial utilizing P-APRV
First author Year n Study design %CPAP TLow Findings





APRV + SB had increased
oxygenation and MAP and
decreased atelectasis
Walsh [58] 2011 20 Retrospective case
series
CPPV vs. APRV
>80 % 50–75 %
PEF
APRV improved pulmonary
blood flow after tetralogy of
fallot repair or cavopulmonary
shunt
Andrews [50] 2013 66,099 Retrospective review
CPPV vs. early APRV
90 % 75 % PEF Early APRV decreased ARDS
incidence tenfold and mortality
threefold
Kawaguchi [53] 2014 13 Retrospective case
series
CPPV vs. APRV
90 % 50–75 %
PEF
APRV safe in pediatric ARDS
without hemodynamic
compromise




APRV had no mortality effect
compared to oscillatory ventilation
as rescue treatments
Number of studies: 5
TLow time at low pressure, CPPV conventional positive pressure ventilation, LTV low tidal volume ventilation, PEF peak
expiratory flow, SB spontaneous breathing
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were used in the animals studies with the majority of studies using swine (Table 1).
In only two of the animal studies were the %CPAP set at ≤80 % of the total cycle
time (Table 1) [22, 23]. In one study, %CPAP was set very short at 25 % of the
breath cycle time [5]. When both the animal and human studies were analyzed 23/
45 studies set %CPAP ≤67 % of the breath and 13/45 had an indeterminate %CPAP
(Tables 1 and 3).
Expiratory duration
In addition, the TLow in both animal and human studies was prolonged to levels seen in
conventional mechanical ventilation (Fig. 1) [3, 9, 15, 16, 24, 25, 43]. Aside from two
Fig. 2 Method of setting expiratory duration (TLow). a Typical personalized airway pressure release ventilation
(P-APRV) airway pressure and flow curves. Correctly set P-APRV has a very brief release phase (time at low
pressure—TLow) and CPAP phase (time at high pressure—THigh) [6]. The THigh is ~90 % of each breath. The two
other P-ARPV settings are the pressure at inspiration (PHigh) and at expiration (PLow). TLow is sufficiently brief such
that end-expiratory pressure (PLow) never reaches 0 cmH2O measured by the tracheal pressure (green line). b
Maintain alveolar stability by adaptively adjusting the expiratory duration as directed by the expiratory flow
curve. The rate of lung collapse is seen in the normal (slope 45°) and acutely injured lung (ARDS, slope 30°).
ARDS causes a more rapid lung collapse due to decreased lung compliance. Our preliminary studies have
shown that if the end-expiratory flow (EEF; −45 L/min) to the peak expiratory flow (PEF; −60 L/min) ratio is
equal to 0.75, the resultant TLow (0.5 s) is sufficient to stabilize alveoli [54, 55]. The lung with ARDS collapses
more rapidly such that the EEF/PEF ratio of 75 % identifies an expiratory duration of 0.45 s as necessary to
stabilize alveoli. Thus, this method of setting expiratory duration is adaptive to changes in lung pathophysiology
and personalizes the mechanical breath to each individual patient
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studies [30, 38], the TLow remained fixed or was titrated based on the PCO2 as opposed
to being adjusted based on changes in lung mechanics using the expiratory flow curve
(Fig. 2). The PHigh was titrated very differently in the studies reviewed, with a range be-
tween 10 cmH2O [2, 21, 28, 29, 31] and 35 cmH2O [3, 37] depending on whether the
target was maximal oxygenation, maximal lung recruitment, or a specific tidal vol-
ume. In addition, most of the studies in the F-APRV group set a positive PLow >
0 cmH2O [2, 4, 7–11, 13, 14, 16, 18–23, 26, 40].
Outcome
The majority of the studies in the F-APRV group were crossover experiments, repre-
senting 59 % of the animal studies (Table 1) and 48 % of the human trials (Table 3)
[2, 4, 7, 9, 10, 12–14, 17, 19, 21, 23, 32], with the primary goal to demonstrate that
APRV could be safely used without adverse effects on lung function or hemodynamic
characteristics. Many crossover trials showed similar or increased oxygenation with
lower peak pressures and no negative effect on hemodynamics with APRV as com-
pared with CPPV [2, 3, 17, 27–32, 39–42], and some studies showed hemodynamic
improvement with APRV [13, 24, 36, 39]. Prospective randomized trials comparing
APRV and CPPV showed that APRV is safe and potentially beneficial (Table 3). In
none of the studies included in this review did APRV cause a significant negative im-
pact on the physiologic process being studied, and in some prospective randomized
studies, APRV was shown beneficial (Tables 1 and 3).
P-APRV
Similar to the F-APRV studies, P-APRV either resulted in improved outcomes or no
change as compared with CPPV and in none of the studies was APRV shown to be
harmful. Unlike the F-APRV studies that were mainly crossover studies, all of the P-
APRV animal studies were randomized prospective cohort trials that compare non-
protective CPPV or low tidal volume (LTV) with APRV [5, 49, 52, 54, 55, 57, 61, 62].
P-APRV was shown to reduce heterogeneity and both alveolar and alveolar duct micro-
strain (i.e., change in alveolar size with applied stress) [54–56] suggesting a mechanism
for the improvement in the efficacy experiments (Table 3) [5, 49, 57, 61, 62].
Discussion
There has been no consensus on what parameters are essential to define a mechanical
breath as being APRV, and thus, APRV settings have been inconsistent over the three
decades since it was first described. However, no studies have shown that APRV is
harmful or significantly inferior as compared with conventional mechanical ventilation.
In 2005, Habashi clearly defined the settings for what we have termed personalized
APRV or P-APRV [6]. P-APRV has a prolonged THigh and very brief TLow duration,
which is set by lung mechanics using the change in the slope of the expiratory flow
curve [6]. Not only is the TLow very brief in P-APRV, it is set by analyzing the slope of
the expiratory flow curve and therefore adaptive to changes in the patient’s lung me-
chanics (Fig. 2b). Using these precisely controlled APRV settings, a number of studies
have shown that P-APRV recruits and stabilizes the alveoli and alveolar ducts [54–56]
and reduces the incidence of ARDS in multiple animal models [5, 57, 62]. A meta-
analysis has shown a reduction in ARDS incidence in trauma patients [53]. Given this
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lack of consensus on how APRV should be set, the remainder of the “Discussion” will
be divided into the results obtained from the F-APRV and P-APRV subgroups, rather
than discuss the findings from each experiment with a different %CPAP, TLow, and/or
PHigh settings.
F-APRV studies
Since, as previously mentioned, most of the animal and human studies were crossover
experiments (i.e., switching from CPPV or spontaneous breathing to F-APRV in the
same animal or patient), the majority of published APRV studies do not address efficacy
(i.e., is APRV superior to conventional ventilation). It is important to note that APRV
did not cause a significant negative impact, as compared with CPPV or spontaneous
breathing, on the physiologic parameters that were measured in any of the crossover
studies (Table 1 and 3). In the randomized prospective animal studies, F-APRV was
shown to be beneficial. It was shown that APRV reduced lung water and HMGB1 in
rabbits [18], improved systemic and cerebrospinal blood flow in swine [16], improved
oxygenation and attenuated ventilator-induced lung injury (VILI) in rabbits [26], and
improved oxygenation and reduced lung injury in swine [7].
In humans, Putsenen et al. showed that APRV with spontaneous breathing in-
creased oxygenation, cardiac index, and pulmonary compliance, with reduced seda-
tive requirements compared with CPPV in humans [39]. Varpula et al. reported
similar mortality and ventilator-free days for APRV and CPPV, and also demon-
strated that it is feasible to utilize APRV with prone positioning. In that study,
TLow was set specifically to allow expiratory flow to reach zero, which would allow
the lung to collapse during expiration [43, 44]. Maxwell et al. showed no difference
between low tidal volume ventilation (LTV) and APRV regarding mortality, ventila-
tor days, ICU length of stay, or complication rates despite increased baseline dis-
ease severity in the APRV group [38]. In human retrospective trials, the APRV
methodology used was not consistent among the studies analyzed (Table 3). Des-
pite these inconsistencies, Gonzalez et al. showed that APRV reduced peak inspira-
tory pressure (PIP) while maintaining similar oxygenation levels [32]. Hanna et al.
showed increased PaO2/FiO2 (P/F) ratio, lung procurement rate, and graft survival
when used in organ donors where the lungs were transplanted [33].
A retrospective study examining trauma patients by Maung et al. demonstrated in-
creased ventilator days on APRV compared with an unspecified method of CPPV [47].
However, this study excluded all mortality in the interest of investigating weaning and
the baseline characteristics of the groups were different, with more severe chest trauma
and decreased P/F ratio at the start in the APRV group. Further, this study used respira-
tory therapist-guided protocol weaning only in the CPPV group, whereas the APRV
group had random, non-protocolized weaning based on physician guidance.
P-APRV
Despite defining the role of tidal volume (Vt) and plateau pressure on VILI in ARDS
patients [63], our current understanding of the parameters comprising the mechanical
breath that either propagate or impede progressive acute lung injury (ALI) is incom-
plete. The mechanism of VILI is believed to be the evolution from a normal homoge-
nously ventilated lung into a heterogeneously ventilated lung, with collapse and
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edema-filled alveoli adjacent to open alveoli. This heterogeneity results in stress con-
centrators and recurrent alveolar collapse and reopening with each tidal breath that
amplify lung tissue injury, instigated by the initial insult such as sepsis, trauma, or
pneumonia [64–66]. Thus, the ventilation strategy that restores or maintains homo-
geneity would minimize VILI and obstruct progressive ALI [64, 66, 67].
P-APRV uses a 90 % CPAP phase that recruits alveoli resulting in homogeneous lung
inflation (Fig. 2a) and a brief release phase with the TLow personalized to the mechanics
of the lung (Fig. 2b) producing a nearly static ventilated lung, which prevents alveolar
collapse and reopening, thereby reducing dynamic tissue strain [54, 56]. The question
is, do these APRV settings that stabilize alveoli protect the lung?
In prospective outcome animal experiments, P-APRV resulted in an increase in oxy-
genation along with a decrease in histopathologic injury as compared with CPPV and
LTV ventilation strategies [5, 52, 57, 61, 62]. Several studies showed that P-APRV re-
sulted in an increase in surfactant protein concentration [5, 57, 62], while two showed
a reduction of inflammatory markers (Table 2) [49, 57].
Kollisch-Singule et al. [54–56] conducted three micro-anatomic studies (i.e., al-
veoli and alveolar ducts) that demonstrated reduced alveolar and conducting airway
micro-strain as well as increased alveolar homogeneity using P-APRV in which the
TLow was set to maintain an EEF/PEF ratio 75 or 10 %. The TLow set using an
EEF/PEF ratio of 75 % was sufficiently short to stabilize alveoli and prevent alveo-
lar collapse, whereas extending the TLow (EEF/PEF ratio 10 %) resulted in alveolar
collapse and instability. These studies add mechanistic support to efficacy studies
showing that preemptive P-APRV reduced ARDS incidence in a clinically applicable
porcine ARDS model [5, 57].
Davies et al. [52] showed increased oxygenation with P-APRV as compared with LTV,
with no significant differences in cerebral ischemia in a swine model of concomitant
brain and lung injury (Table 2). In patients, Yoshida et al. [60] demonstrated increased
oxygenation and mean arterial pressure (MAP) with decreased atelectasis using P-
APRV as compared to LTV ventilation. Walsh et al. [58] showed improved pulmonary
blood flow when using P-APRV versus CPPV ventilation post-operatively after tetratol-
ogy of Fallot repair or cavopulmonary shunt in neonates (Table 4).
Furthermore, Andrews et al. [50] in a meta-analysis showed a tenfold decrease in
ARDS incidence as well as a threefold decrease in mortality when compared to trauma
patients with similar injuries that were treated with standard of care ventilation in 15
trauma intensive care units (Table 4). However, all of the human trials testing the P-
APRV method [50, 53, 58–60] are retrospective studies, and as such, it is not clear that
the precise P-APRV settings were followed, aside from the study by Andrews et al. [50]
that strictly adhered to the P-APRV protocol throughout the study in trauma patients.
Despite this, the human results are in concordance with multiple animal studies [5, 49,
54–57, 61, 62] that support the clinical data [50] that P-APRV may be used to reduce
the incidence of acute respiratory distress syndrome (ARDS) more effectively than con-
ventional LTV ventilation applied early or after the onset of ARDS.
A note on mechanical ventilators
An often under-analyzed aspect of mechanical breath delivery is the ventilator used to
deliver the breath. Every ventilator has a specific design with differing resistances built
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into the ventilator gas path, responses to spontaneous ventilation, as well as software
quirks that affect breath delivery. APRV may be named in various ways based on the
ventilator in use such as (1) APRV (Dr ger Evita, Savina and V series, Hamilton G5),
(2) Bi-Vent (Maquet Servo-i), (3) BiLevel (Engström Carestation, Puritan Bennett 840
& 980), and (4) APRV/Biphasic (Viasys Avea). However, even more problematic than
the different names is the wide variation in their implementation of APRV.
In particular, the ability to control key APRV parameters such as the TLow varies, and
fine control of this parameter is critical to properly set P-APRV (Fig. 2b). APRV strat-
egies on some ventilators have deviated from the original concept of a timed CPAP
with a release phase, by adding pressure support (PS). This requires a trigger that cre-
ates a need for synchronization with the ventilator resulting in automated changes to
both the inspiratory and expiratory duration. More specifically, the TLow, which is crit-
ical to control end-expiratory lung volume and prevent airway closure, spontaneously
adjusts when PS is added to this mode on these ventilators, regardless of the TLow set-
ting, producing large and variable tidal volumes leading to lung volume loss and alveo-
lar instability. So, even if APRV was set accurately by the clinician, the ventilator may
automatically adjust the duration of the release phase (TLow) ultimately allowing the
lung to collapse. This effect would be similar to conventional ventilation automatically
adjusting Vt or PEEP without physician input.
Furthermore, many researchers define APRV as “extreme” inverse-ratio pressure-
control ventilation (IR-PCV). However, unlike IR-PCV, P-APRV does not set a defined
I:E ratio. Rather, the CPAP phase is briefly interrupted by a “release phase” (i.e., TLow)
that is established by independently setting a TLow based upon analysis of the expiratory
flow curve. Further, patients can breathe spontaneously throughout the entire respira-
tory cycle in APRV, superseding the set I:E ratio. Unfortunately, many times the exact
make and model of the ventilator was not reported in the papers reviewed, and thus,
we could not categorize studies by the ventilator used, but it is an important factor to
consider if the ventilator being used can accurately deliver P-APRV.
Current state of APRV and clinical implications
As described previously, there is a paucity of data testing APRV with identical settings,
especially in clinical trials almost all of which were retrospective or crossover studies.
Rose et al. [68] reviewed the literature in 2008 and concluded that there is a lack of
consistency in APRV settings making comparison with conventional ventilator strat-
egies difficult. Another recent review by Facchin et al. [69] examined the current lit-
erature for both APRV and high-frequency oscillatory ventilation (HFOV) for
treatment and prevention of ARDS; the authors concluded that there is inconsistent
evidence and a lack of high quality trials to make conclusions regarding APRV or
HFOV efficacy.
It is clear from the studies examined in this review that APRV has evolved from a
mechanical breath defined as a prolonged CPAP phase with a brief release phase [1]
into a highly sophisticated, dynamic mechanical breath with precise settings that are re-
sponsive to changes in lung physiology (i.e., P-APRV) [6]. Although the mechanical
breath used by both Downs and Habashi are referred to as APRV, the actual mechan-
ical breath created by each is very different (Fig. 1a, d) [2, 57] as is the breath created
and studied in other experiments [3, 9] (Fig. 1b, c). The current use of the APRV
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acronym remains an imprecise term that demands a specific definition of parameter
settings to be utilized consistently. Obviously, some APRV settings are going to super-
ior to others in their ability to protect the lung.
P-APRV appears to be an exciting and novel open lung strategy that may significantly
reduce ARDS incidence, morbidity, and mortality of established ARDS. Data suggests
that rather than overdistending alveoli, the extended THigh/PHigh redistributes gas from
the alveolar ducts to the alveoli, where it belongs [54, 55] and changes heterogeneous
to homogeneous alveolar ventilation [56]. The calculated strain on alveoli was signifi-
cantly reduced demonstrating that mechanical stretch on the alveolar wall was de-
creased. These data have led us to conclude that the extended inspiratory duration has
a powerful positive impact on reducing strain at the alveolar level. We hypothesize that
the mechanism of this protection (i.e., reduce alveolar strain) is secondary to increased
lung volume and the number of recruited alveoli. The extended THigh “nudges” open al-
veoli over a several hours in a non-pathologic manner resulting in open lung ventila-
tion. Since the lung becomes fully recruited with significantly improved compliance,
even with relatively high tidal volumes (10–14 cm3/kg), the driving pressure is not in-
creased (unpublished observations).
Conclusions
Although many settings have been used, none of the studies reviewed showed a worse
outcome using APRV as compared with CPPV, with many studies showing significant
benefits in cardiopulmonary variables. The evolution of APRV methodology has been
drastic from Downs and Stock (F-APRV) [1] to the P-APRV method of Habashi [6]. P-
APRV allows for a personalized control of lung stability on a breath-to-breath basis that
is not possible with other modes of ventilation. P-APRV is an adaptive, flow directed,
duration dependent ventilation strategy that adapts the setting to each patient regard-
less of their lung pathophysiology. This personalized, adaptive mechanical breath may
prove more efficacious at treating and preventing ARDS than the current standard of
care. Ultimately, more studies are needed using consistent and well-defined settings to
identify the optimal APRV breath necessary to maximize lung protection.
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